Cirsium japonicum var. Maackii Improves Cognitive Impairment under Amyloid Beta25-35-Induced Alzheimer's Disease Model

Biomed Res Int. 2022 Jan 7:2022:4513998. doi: 10.1155/2022/4513998. eCollection 2022.

Abstract

Abnormal production and degradation of amyloid beta (Aβ) in the brain lead to oxidative stress and cognitive impairment in Alzheimer's disease (AD). Cirsium japonicum var. maackii (CJM) is widely used as an herbal medicine and has antibacterial and anti-inflammatory properties. This study focused on the protective effect of the ethyl acetate fraction from CJM (ECJM) on Aβ 25-35-induced control mice. In the T-maze and novel object recognition test, ECJM provided higher spatial memory and object recognition compared to Aβ 25-35 treatment alone. In the Morris water maze test, ECJM-administered mice showed greater learning and memory abilities than Aβ 25-35-induced control mice. Additionally, ECJM-administered mice experienced inhibited lipid peroxidation and nitric oxide production in a dose-dependent manner. The present study indicates that ECJM improves cognitive impairment by inhibiting oxidative stress in Aβ 25-35-induced mice. Therefore, CJM may be useful for the treatment of AD and may be a potential material for functional foods.

MeSH terms

  • Alzheimer Disease / chemically induced
  • Alzheimer Disease / drug therapy*
  • Alzheimer Disease / physiopathology
  • Amyloid beta-Peptides / toxicity*
  • Animals
  • Cirsium / chemistry*
  • Cognitive Dysfunction / chemically induced
  • Cognitive Dysfunction / drug therapy*
  • Cognitive Dysfunction / etiology
  • Cognitive Dysfunction / physiopathology
  • Disease Models, Animal
  • Humans
  • Male
  • Mice
  • Mice, Inbred ICR
  • Peptide Fragments / toxicity*
  • Plant Extracts / chemistry
  • Plant Extracts / pharmacology*

Substances

  • Amyloid beta-Peptides
  • Peptide Fragments
  • Plant Extracts
  • amyloid beta-protein (25-35)